Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
LONDON, Aug. 21, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 122.5 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company’s issued share capital.
The notification of dealing form can be found below.
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] |
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / James White | |
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 |
| Simon Conway / Natalie Garland-Collins | [email protected] |
| ICR, Inc. (US Media and Investor enquiries) | |
| Darcie Robinson | Tel: +1 203-682-8379 [email protected] |
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | David Ebsworth | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Chairman | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Verona Pharma plc | |
| b) | LEI | 213800EVI6O6J3TIAL06 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 5 pence each | |
| Identification code | GB00BYW2KH80 | ||
| b) | Nature of the transaction | David Ebsworth purchased 8,130 Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 122.5 pence per Ordinary Share | 8,130 Ordinary Shares | ||
| d) | Aggregated information | N/A | |
| - Aggregated volume | |||
| - Price | |||
| e) | Date of the transaction | 17 August 2017 | |
| f) | Place of the transaction | London Stock Exchange, AIM | |
